NEW YORK, Aug. 8, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims of whether the board members of NxStage Medical, Inc. ("NxStage" or the "Company") (NASDAQ: NXTM) breached their fiduciary duties. NxStage investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/nxtm.
On August 7, 2017, Fresenius Medical Care announced the acquisition of medical technology company NxStage for $2 billion. Under the terms of the agreement, NxStage shareholders will receive only $30.00 in cash for each common stock of NxStage that they own.
The investigation focuses on whether the NxStage board members failed to fulfill their duties to the shareholders and whether Fresnius Medical Care is underpaying for NxStage.
If you are a shareholder of NxStage and would like to learn more about this investigation, you can visit the firm's site: www.bgandg.com/nxtm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
SOURCE Bronstein, Gewirtz & Grossman, LLC